Gerresheimer reported a 15.7% increase in revenue in the first half of 2025.
This was partially due to the inclusion of Bormioli Pharma, which was acquired in 2024.
Revenue in the first half of the year rose by 15.7% to €1,120.7 million (H1 2024: €968.5 million).
Adjusted EBITDA increased by 11.8% to €210.4 million (H1 2024: €188.2 million).
Dietmar Siemssen, CEO of Gerresheimer, said: “Gerresheimer is a strong, resilient company. Despite a challenging market environment, we already returned to organic growth in the second quarter, even though growth momentum in the first half of the year overall was below our expectations.
“With our strategic transformation into a system and solution provider, the acquisition of Bormioli Pharma, and the expansion of our product portfolio to include solutions for biologics, we will once again grow significantly faster than the overall market in the medium and long term.”
Glass division
The Primary Packaging Glass division generated revenues of €474.9 million in the first half of 2025 (H1 2024: €426.5 million).
In absolute terms, revenues rose by 11.3% due to the inclusion of Bormioli Pharma.
Organic revenues declined by 7.6% compared with the pro forma figures for the first half of 2024.
This was due to subdued demand in the cosmetics market and a decline in demand in containment solutions for oral liquid medications, which the company considers to be temporary.
Adjusted EBITDA rose by 14.7% to €85.2 million (H1 2024: €74.2 million).
In organic terms, adjusted EBITDA was 3.3% below the pro forma figures for the same period of the previous year.
The adjusted EBITDA margin reached 17.9% (H1 2024: 17.4%).
The margin expansion is attributable to a higher share of high value solutions in the product mix, including ready-to-fill injection vials, for example.
Stronger second half
Gerresheimer expects stronger growth in the second half of 2025.
The strongest driver will be the ramp-up of new production lines for medical devices.
In addition, the expanded portfolio of high-value solutions will contribute to growth, particularly systems and solutions for biologics.
The resumption of full production at the Lohr, Germany, and Morganton, USA, sites will also have a positive impact.
